Cravath Reps Mylan In $9.9B Deal For Swedish Drugmaker
Mylan announced on Wednesday that it has agreed to acquire Swedish drug company Meda AB in a $9.9 billion cash-and-stock deal guided by Cravath Swaine & Moore LLP, three months after...To view the full article, register now.
Already a subscriber? Click here to view full article